

Medibio Completes Development of Corporate Stress Product

- **Development of a first cloud based scalable ECG storage and analytics platform**
- **Successfully closed the loop on end to end automation of entire infrastructure**
- **Live streaming from ECG monitor; to phone app; cloud; algorithms; results back to phone**
- **Opens the way for several Corporate and Commercial Partnership discussions to advance**

Sydney, Australia – 21 August 2015: Medibio Limited (**MEB** or the **Company**) is pleased to announce an update on the development of its Corporate Stress Product and its planned commercial launch.

MEB has completed the development and testing of a world first cloud based scalable Corporate Stress Product including real-time ECG Data Streaming, Algorithm Processing and Data Analytics.

MEB has successfully tested end-to-end automation including streaming of live data: from a range of ECG monitors via the front end App on a range of smart phones; to its cloud based proprietary Algorithms and Data Analytics solution; and near real-time results back to the front-end App.

Despite leveraging off the Amazon Web Services (AWS) platform much of the technology needed to create such a product did not exist making MEB's commercial product unique in this category.

With the completion of its highly scalable Corporate Stress Product, MEB is now ready to move into the final stage of Product Release (Commercial Launch). MEB is already in the process of presenting to a number of potential commercial partners.

World Leading Design of Front-End Application

MEB has partnered with Isobar, one of the world's largest digital agencies, to complete the front-end application for the commercial offering. MEB has leveraged Isobar's leading design capability to develop and test a world class front-end application. The front-end application includes a range of interventions designed to assist with the reduction of stress in the workplace. These interventions have been developed by Clinical Psychologists and are tailored to the stress categories of Mild, Moderate and Serious. Not only are the interventions uniquely designed to focus on stress, they will form a major element of future commercial validation trials, resulting in MEB's ability to claim one of the few commercially validated stress interventions globally.

During further product development, functionality will be increased to ensure that the application will be integrated into the employees every day lives with features such as the ability to view their heart-rate real time to assist with daily stress management, daily stress reduction activities, geo-tracking and others.

World Leading Cloud-based Infrastructure

MEB's has partnered with AWS, the world's leading cloud platform provider, to deliver a highly reliable, scalable and secure infrastructure to enable real-time Data Streaming, Algorithm Processing, and Data Analytics and reporting. Using AWS for cloud-based infrastructure, MEB has created the first of its kind relating to these four aspects. MEB has established an end-to-end solution streaming data from an ECG device, through the front end App, written new algorithms that can determine the sleep period from the data without the use of the accelerometer, push it through MEB's patented stress algorithm, and stream back a result onto the front end App.

The data is encrypted to comply with current privacy legislation, and when stored is HIPPA compliant in line with the U.S medical standard. As a result this infrastructure can be used for all three of the future commercial pillars for MEB, namely the Corporate Stress Product, Consumer App, and, post FDA approval, the Medical product.

Further Information:		Website: www.medibio.com.au	
Medibio Shareholder Enquiries to: Kris Knauer CEO and Director Medibio Limited kris.knauer@medibio.com.au T: +61 (0)411 885 979		Medibio Media Enquiries to: Peter Taylor NWR Communications Peter@nwrcommunications.com.au T: +61 (0)412 036 231	

About Medibio Limited

Medibio (ASX: MEB), is a medical technology company developing a new objective evidence based test to assist in the diagnosis of depression, other mental health disorders and chronic stress. This test utilizes circadian heart rate variability. The technology is based on the scientific finding that circadian heart rate variability is a sensitive measure for depression, other mental health disorders and chronic stress. The technology consists of a heart monitor that sends ECG recordings wirelessly to the internet where a proprietary algorithm suite analyses and delivers a quantifiable measure which can be used by a clinician to assist in diagnosis. The Technology has the potential to be the first FDA Approved objective, evidence based approach to the diagnosis of depression and other mental health disorders. The technology has already benefited from 10 years of laboratory research and Medibio is undertaking a number of pivotal studies to validate its clinical utility.